Search company, investor...


Founded Year



Unattributed VC - II | Alive

Total Raised


Last Raised

$10.8M | 23 yrs ago

About Asterion

Asterion is a manufacturer of analog semiconductors.

Headquarters Location

450 Donald J. Lynch Boulevard Suite D

Marlborough, Massachusetts, 01752,

United States


Missing: Asterion's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Asterion's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Asterion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Asterion is included in 1 Expert Collection, including Semiconductors, Chips, and Advanced Electronics.


Semiconductors, Chips, and Advanced Electronics

6,168 items

Companies in this collection develop everything from microprocessors to flash memory, integrated circuits specifically for quantum computing and artificial intelligence to OLED for displays, massive production fabs to circuit design firms, and everything in between.

Asterion Patents

Asterion has filed 1 patent.

The 3 most popular patent topics include:

  • DNA
  • DNA repair
  • Genetics
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, G protein coupled receptors, Amino acids, Proteins


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, G protein coupled receptors, Amino acids, Proteins



Latest Asterion News

Marguerite joins Asterion's Italian fibre and data centre holding

Oct 27, 2022

(Telecompaper) Pan-European infrastructure investor Marguerite announced an agreement to sell its 19.6 percent stake in Italian ICT group Irideos to Spanish...

Asterion Frequently Asked Questions (FAQ)

  • When was Asterion founded?

    Asterion was founded in 2001.

  • Where is Asterion's headquarters?

    Asterion's headquarters is located at 450 Donald J. Lynch Boulevard, Marlborough.

  • What is Asterion's latest funding round?

    Asterion's latest funding round is Unattributed VC - II.

  • How much did Asterion raise?

    Asterion raised a total of $14M.

  • Who are the investors of Asterion?

    Investors of Asterion include Menlo Ventures, Pacific Life Insurance, Alexander Hutton Venture Partners and Comdisco Ventures.

  • Who are Asterion's competitors?

    Competitors of Asterion include CVRx, Bellicum Pharmaceuticals, TxCell, Intercept Pharmaceuticals, Pearl Therapeutics and 11 more.

Compare Asterion to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Phytomedics is a biopharmaceutical company based in New Jersey with a broad portfolio of novel compounds for chronic diseases. The lead compound is in clinical development and has shown extraordinary results in clinical trials for the treatment of auto immune disorders like rheumatoid arthritis. The company's platform technology is the basis of their large portfolio of novel therapeutic compounds.


Cryptopharma is a Company focused on the discovery and development of anti-inflammatory therapeutic agents for treatment of pulmonary diseases. The company's initial focus is on the development of CP92, a treatment of Cystic Fibrosis. Second generation compounds are in development with the potential to treat other inflammatory conditions including asthma and chronic obstructive pulmonary disease (COPD). See

TxCell Logo

TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.


Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Anza Therapeutics

Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.